Corrigendum to "Novel Splice Variants of sFlt1 are Upregulated in Preeclampsia [Placenta 30 (3) (2009) 250-255]" (DOI:10.1016/j.placenta.2008.12.010);Novel Splice Variants of sFlt1 are Upregulated in Preeclampsia

Placenta

Volumn 30, Issue 3, 2009, Pages 250-255

  Heydarian, M ^a   McCaffrey, T ^a   Florea, L ^b   Yang, Z ^a   Ross, M M ^c   Zhou, W ^c   Maynard, S E ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^b George Washington University   (United States)

^c GEORGE MASON UNIVERSITY   (United States)

Author keywords

Hypertension; Placenta; Preeclampsia; Pregnancy

Indexed keywords

PROTEIN SFLT1; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; CYTOTROPHOBLAST; FEMALE; HUMAN; HUMAN TISSUE; NUCLEOTIDE SEQUENCE; PLACENTA; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN VARIANT; UPREGULATION;

EID: 59849090604     PISSN: 01434004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.placenta.2009.02.003     Document Type: Erratum

References (28)

1. Walker J.J. Pre-eclampsia. Lancet 356 9237 (2000) 1260-1265
2. ACOG Practice Bulletin. Diagnosis and management of preeclampsia and eclampsia. Number 33, January 2002. American College of Obstetricians and Gynecologists. Int J Gynaecol Obstet 77 1 (2002) 67-75
3. Duley L. Maternal mortality associated with hypertensive disorders of pregnancy in Africa, Asia, Latin America and the Caribbean. Br J Obstet Gynaecol 99 7 (1992) 547-553
4. Mackay A.P., Berg C.J., and Atrash H.K. Pregnancy-related mortality from preeclampsia and eclampsia. Obstet Gynecol 97 4 (2001) 533-538
5. Zhou Y., Damsky C.H., and Fisher S.J. Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome?. J Clin Invest 99 9 (1997) 2152-2164
6. Zhou Y., McMaster M., Woo K., Janatpour M., Perry J., Karpanen T., et al. Vascular endothelial growth factor ligands and receptors that regulate human cytotrophoblast survival are dysregulated in severe preeclampsia and hemolysis, elevated liver enzymes, and low platelets syndrome. Am J Pathol 160 4 (2002) 1405-1423
7. Roberts J.M., Taylor R.N., Musci T.J., Rodgers G.M., Hubel C.A., and McLaughlin M.K. Preeclampsia: an endothelial cell disorder. Am J Obstet Gynecol 161 5 (1989) 1200-1204
8. Ferris T.F. Pregnancy, preeclampsia, and the endothelial cell. N Engl J Med 325 20 (1991) 1439-1440
9. Maynard S.E., Min J.Y., Merchan J., Lim K.H., Li J., Mondal S., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111 5 (2003) 649-658
10. Lu F., Longo M., Tamayo E., Maner W., Al-Hendy A., Anderson G.D., et al. The effect of over-expression of sFlt-1 on blood pressure and the occurrence of other manifestations of preeclampsia in unrestrained conscious pregnant mice. Am J Obstet Gynecol 196 4 (2007) 396 e1-e7
11. Gilbert J.S., Babcock S.A., and Granger J.P. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 50 6 (2007) 1142-1147
12. Makris A., Thornton C., Thompson J., Thomson S., Martin R., Ogle R., et al. Uteroplacental ischemia results in proteinuric hypertension and elevated sFlt-1. Kidney Int 71 10 (2007) 977-984
13. Levine R.J., Maynard S.E., Qian C., Lim K.H., England L.J., Yu K.F., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350 7 (2004) 672-683
14. Vatten L.J., Eskild A., Nilsen T.I., Jeansson S., Jenum P.A., and Staff A.C. Changes in circulating level of angiogenic factors from the first to second trimester as predictors of preeclampsia. Am J Obstet Gynecol 196 3 (2007) 239 e1-e6
15. Kim S.Y., Ryu H.M., Yang J.H., Kim M.Y., Han J.Y., Kim J.O., et al. Increased sFlt-1 to PlGF ratio in women who subsequently develop preeclampsia. J Korean Med Sci 22 5 (2007) 873-877
16. Eremina V., Jefferson J.A., Kowalewska J., Hochster H., Haas M., Weisstuch J., et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 358 11 (2008) 1129-1136
17. Kendall R.L., and Thomas K.A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90 22 (1993) 10705-10709
18. Florea L., Hartzell G., Zhang Z., Rubin G.M., and Miller W. A computer program for aligning a CDNA sequence with a genomic DNA sequence. Genome Res 8 9 (1998) 967-974
19. Florea L., Di Francesco V., Miller J., Turner R., Yao A., Harris M., et al. Gene and alternative splicing annotation with air. Genome Res 15 1 (2005) 54-66
20. Camerini S., Polci M.L., Liotta L.A., Petricoin E.F., and Zhou W. A method for the selective isolation and enrichment of carrier protein-bound low-molecular weight proteins and peptides in the blood. Proteomics Clin Appl 1 2 (2007) 176-184
21. Luchini A., Geho D.H., Bishop B., Tran D., Xia C., Dufour R.L., et al. Smart hydrogel particles: biomarker harvesting: one-step affinity purification, size exclusion, and protection against degradation. Nano Lett 8 1 (2008) 350-361
22. Thomas C.P., Andrews J.I., and Liu K.Z. Intronic polyadenylation signal sequences and alternate splicing generate human soluble Flt1 variants and regulate the abundance of soluble Flt1 in the placenta. FASEB J 21 14 (2007) 3885-3895
23. Sela S., Itin A., Natanson-Yaron S., Greenfield C., Goldman-Wohl D., Yagel S., et al. A novel human-specific soluble vascular endothelial growth factor receptor 1: cell type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ Res 102 12 (2008) 1566-1574
24. Wain H.M., Bruford E.A., Lovering R.C., Lush M.J., Wright M.W., and Povey S. Guidelines for human gene nomenclature. Genomics 79 4 (2002) 464-470
25. Hertig A., Berkane N., Lefevre G., Toumi K., Marti H.P., Capeau J., et al. Maternal serum sFlt1 concentration is an early and reliable predictive marker of preeclampsia. Clin Chem 50 9 (2004) 1702-1703
26. Chung J.Y., Song Y., Wang Y., Magness R.R., and Zheng J. Differential expression of vascular endothelial growth factor (VEGF), endocrine gland derived-VEGF, and VEGF receptors in human placentas from normal and preeclamptic pregnancies. J Clin Endocrinol Metab 89 5 (2004) 2484-2490
27. Tsatsaris V., Goffin F., Munaut C., Brichant J.F., Pignon M.R., Noel A., et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 88 11 (2003) 5555-5563
28. Lindheimer M.D., and Umans J.G. Explaining and predicting preeclampsia. N Engl J Med 355 10 (2006) 1056-1058